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Abstract
We attempted to gather information on the pathogenesis of medication-overuse headache, as well as on the neurochemical
mechanisms through which symptomatic medication overuse concurs to headache chronification. Transcriptional profiles were
therefore evaluated as an index of the homeostasis of the trigeminovascular system in the trigeminal ganglion of female rats exposed
for 1 month to daily oral doses of eletriptan or indomethacin. We report that both drug treatments change trigeminal ganglion gene
expression to a similar extend. Of note, qualitative transcriptomic analysis shows that eletriptan and indomethacin prompt nearly
identical, increased expression of genes coding for proteins involved inmigraine pathogenesis and central pain sensitization such as
neuropeptides, their cognate receptors, prostanoid, and nitric oxide–synthesizing enzymes, as well as TRP channels. These genes,
however, were not affected in thoracic dorsal root ganglia. Of note, lowering of orofacial nociceptive thresholds, as well as forepaw
hyperalgesia occurred in both indomethacin- and eletriptan-treated rats. Our study reveals that chronic rat exposure to 2 acute
headache medications with completely different mechanisms of action prompts pain sensitization with highly similar induction of
pronociceptive genes selectively within the trigeminal ganglion. Data further our understanding of medication-overuse headache
pathogenesis and provide hints for specific mechanism–based treatment options.
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1. Introduction
Medication-overuse headache (MOH) is a debilitating, chronic
headache with a 1-year prevalence of 1% to 2%.13,21 Whether
MOH is a biological entity that differs from chronic daily headache
and shows specific neurobiological and genetic background is
a matter of debate.23 Although MOH tends to show the same
features regardless of the overused drug, a longitudinal study in
migraineurs suggests that the 1-year probability of migraine
transformation into MOH is higher for barbiturates and pro-
gressively decreases for opioids, triptans, and nonsteroidal
anti-inflammatory drugs (NSAIDs).5 The temporal kinetics char-
acterizing the shift from correct symptomatic therapy to regular
(often daily) overuse also depend on headache severity, age, sex,
and psychological status of the patient.5,6,10 Clinically, MOH
represents a critical condition where a vicious cycle of chronic
headache and regular symptomatic medication intake is
supposed to underlie drug overuse.16 Patients with MOH are
typically refractory to classic preventive treatments, and there is
general agreement that withdrawal from medication overuse is
mandatory to reestablish previous headache features, as well as
sensitivity to headache prophylaxis.2,30,36 Overall, MOH repre-
sents a problem of social health with important therapeutic,
toxicological, and pharmacoeconomic implications.15,33
A great deal of efforts is currently directed at understanding the
molecular and pathophysiological basis that underlies MOH
pathogenesis.14 At present, 2 nonmutually exclusive hypotheses
have been put forward.6 The first is based on the compulsive use
of headache medications shown in some patients with MOH and
considers MOH as an addiction to symptomatic remedies.22,35
According to this interpretation, therefore, dysfunction of classic
reward-seeking central nervous system pathways and drug
dependence lays at the basis of MOH.9 A second hypothesis is
focused on neural sensitization. The latter occurs as a direct
consequence of drug overuse that prompts adaptations of the
trigeminovascular system that translates into pain transmission
facilitation and latent sensitization.17,28 In keeping with this
interpretation, work done in rodent models of MOH suggests
that upregulation of calcitonin gene-related peptide (CGRP) and
nitric oxide (NO) signaling is causative to the processes of
sensitization by triptan overuse.18–20,24 However, it is still
unknown whether these effects are also shared by symptomatic
headache medications different from triptans, and represent
a signature of the neurophysiologic rearrangements that underlie
MOH. Also, the quantitative aspects, in terms of number of
neurotransmitter/neuromodulators involved, that characterize
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the trigeminovascular alterations prompted by repetitive expo-
sure to acute headache remedies still wait to be defined.
Addressing these issues might further our understanding of the
pathophysiology of MOH and headache chronification.
Thus, to gather further information on the neurochemistry of
MOH, in this study, we designed experiments aimed at un-
derstanding whether chronic rat exposure to triptan or NSAID
affects transcriptome of the trigeminal and thoracic dorsal root
ganglia (DRG), and whether these changes were coherent
between the 2 drug classes.
2. Materials and methods
2.1. Animals
Adult female Wistar rats 230 to 250 g (Charles River, Milan, Italy)
were maintained 3 per cage in a climate-controlled room at 236
2˚C on a 12-hour light/dark cycles with free access to food and
water. All animal manipulations were performed according to the
European Community guidelines for animal care (DL 116/92,
application of the European Communities Council Directive 86/
609/EEC).
2.2. Drug administration
Rats were daily treated by oral gavage for 30 days with 0.8 mg/kg
eletriptan (ELE) and 2 mg/kg indomethacin (INDO) dissolved in
100 mL of water. Control animals received the same volume of
water. Both drugs were from Sigma-Aldrich (Milan, Italy). At the
end of the treatments, rats were anesthetized with isoflurane and
killed for tissue extraction. The trigeminal ganglion or thoracic
DRG were removed and frozen in Trizol at 280˚C for RNA
extraction.
2.3. Microarray-based gene expression profiling
The labeling and hybridization stepswere performed according to
the Agilent 2-Color Microarray-Based Gene Expression Analysis
version 5.7 protocol. Pools of RNA from ganglia of ELE- or INDO-
treated rats were contrasted with reference RNA obtained by
pooling equal amount of RNAs from control animals, onWhole rat
genome Agilent 8x60K arrays. Image analysis and quality control
were performed as previously reported.27
Data were clustered in groups of genes that behaved similarly
across the experiments using Cluster 3.0 and Treeview software.
Pathway analysis was performed by means of the GO-Elite
software, version 1.2 using as input data, the list of the
differentially expressed genes from every comparison, with
a threshold at 3 and a statistical significance ,0.05.
The microarray data sets supporting the results of this article
are available in the MIAME public database ArrayExpress
repository (http://www.ebi.ac.uk/arrayexpress/) (Accession
Number E-MTAB-5864).
2.4. Reverse transcript and real-time polymerase
chain reaction
Total RNA from the trigeminal ganglia or thoracic DRGwas isolated
using Trizol Reagent (Life Technologies, Monza, Italy). Reverse
transcript and quantitative polymerase chain reaction (qPCR) were
performed as previously reported.8 The following primers were
used: for VIP forward 59-CAGTTCCTGGCGATCCTGACA-39 and
reverse 59-GGGCGTGTCATTCTCCGCTAAGG-39, PACAP for-
ward 59-TCAGCTTCCCTGGGATCAGACC-39 and reverse
59-GGTCCAAGACTTTGCGGTAGGCTT-39, CGRPa forward
59-GGCATGCGGCCTCCAGGCAG-39 and reverse 59-AGAGCCC-
TCAGCCTCCTGTTCCT-39, SST forward59-AAGTCTCTGGCGGC-
TGCCACC-39 and reverse 59-GCAGCCAGCTTTGCGTTCCCG-39,
TRPV1 forward 59-GCCATGCTCAATCTGCACATTGGG-39 and re-
verse 59-GCTCCATTCTCCACCAAGAGG-39, 5HT1RB forward
59-CATCTCTGTGTCATCGCCCTGGAC-39 and reverse 59-
CGTGGTCGGTGTTCACAAAGCAGT-39, 5HT1RD forward
59-CGAGGAGATGTCTGACTGCCTGGT-39 and reverse 59-
CAGAGCCCGTCATAAGCTGTGCTG-39, COX1 forward
59-GGCCTCGACCACTACCAATGTGAC-39 and reverse 59-
AGTACCAGGCGCATGAGTACTTCTCG-39, COX2 forward
59-GCCGGGTCTGATGATGTATGC-39 and reverse 59-TGGAA-
CAGTCGCTCGTCATCC-39, and18S59-GGGGAATCAGGGTTCGAT-
TCCGG-39and reverse59-GGCACCAGACTTGCCCTCCAATGG-39.
Ten rats per group were used for qPCR analysis.
2.5. Behavioral tests
All behavioral tests were conducted by an experimenter blind to
treatment. On each testing day, the animals were brought into the
behavior room 1 hour before the test session. Plantar or orofacial
allodynia were measured as previously reported.12,32,34 Evalua-
tion of orofacial hyperalgesia was conducted by supraorbital
injection of a low concentration of formalin (0.2%, 20 mL), and
time spent scratching the injected region consisting of an early
short-lasting period (0-10 minutes) followed by a second tonic
phase (10-60 minutes) was monitored with a manual chronom-
eter and considered as indicative of nociception.31 Grimace
score test was conducted as reported.25 Cold sensitivity was
assessed with the hot/cold-plate analgesiometer (Ugo Basile,
Milan, Italy). Animals were allowed to acclimate to the testing
apparatus for 30 minutes, after which they were individually
placed on the center of a cold plate in a transparent Plexiglas
cylinder. The temperature of the cold plate was kept constant at 5
6 1˚C. Pain-related behaviors (ie, lifting and licking of the paw)
were observed, and the time(s) of the first sign was recorded.
Each trial was repeated 3 times at 10-minute intervals, and
a cutoff time of 300 seconds was used to prevent tissue damage.
Von Frey experiments were conducted at day 30, whereas the
formalin test was conducted at day 31 in the same animals. In
a separate group of animals, the cold plate test and CGRP
plasma levels were evaluated at day 31. Behavioral testing
occurred before drug administration. Capsaicin was injected only
once for a single evaluation of CGRP blood content 1 hour after
the cold plate test.
2.6. Calcitonin gene-related peptide plasma levels
One hour later the cold plate test, rats received a single injection of
20mL of 0.2% capsaicin (Sigma Chemical Co, St. Louis, MO) into
the vibrissa pad by means of subcutaneous injection with a 30-
gauge needle. Tenminutes later, blood samples were collected in
heparinized Eppendorf tubes by direct puncture of the retro-
orbital venous plexus. Calcitonin gene-related peptide plasma
concentrations were determined by means of an ELISA kit (Bertin
Pharma, Montigny le Bretonneux, France).
2.7. Data analysis
All numerical data are expressed asmean6SEM. For each single
gene, differences in expression levels were statistically evaluated
comparing treated and untreated conditions using analysis of
variance plus the Tukey post hoc test.
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3. Results
3.1. Transcriptomic analysis in trigeminal ganglia of rats
chronically exposed to ELE or INDO
To establish a model of MOH, we treated adult female rats with
daily oral doses of ELE or INDO for 1 month. ELE was chosen
because it represents an efficacious and widely used triptan,
whereas INDO was selected among the different NSAIDs
because it is one of the most commonly used antimigraine drugs
and frequently overused by patients with MOH in single or
combined formulations. We adopted doses of 0.8 mg/kg for ELE
and 2 mg/kg for INDO in rats that in patients approximately
reproduce an overuse of 60 mg/day of ELE (between 1 and 2
tablets of 40 mg) and 140 mg/day of INDO (between 1 and 2
tablets of 100 mg/day).
The possible impact of both drugs on gene expression
profile in the rat trigeminal ganglion was evaluated by means of
gene-array analysis. After quality control of the 30,367 probe
sets present on the array, 27,297 and 28,393 genes were
considered expressed for ELE and INDO, respectively. To
understand the degree of consistency of the changes induced
by ELE and INDO, we compared the quantitative and
qualitative aspects of the results obtained using a fold change
threshold of 1.4 and 3. As shown in Figure 1A, we found that
with both thresholds the number of genes whose expression
was increased or decreased by INDO and ELE was highly
similar. Specifically, with the threshold set at 1.4, the number
of induced genes was 7664 (28.1%) and 6580 (23.2%) with
ELE and INDO, respectively. When the threshold was raised to
3, induced genes were 2043 (7.5%) and 1621 (5.7%) for ELE
and INDO, respectively (Fig. 1A). Similarly, the number of
genes whose expression was downregulated by 1.4-fold was
7695 (28.2%) with ELE and 6898 (24.3%) with INDO, whereas
with the threshold set at 3 the number of downregulated genes
was 1719 (6.3%) and 1489 (5.2%) for ELE and INDO,
respectively (Fig. 1A).
Figure 1. Gene array transcriptomic analysis in the trigeminal ganglion of rats exposed to chronic treatment with ELE or INDO. (A) The number of genes found
increased or decreased by 1.4- or 3-fold by means of gene array transcriptomic analysis in the trigeminal ganglion of rats exposed to 1-month daily oral treatment
with ELE (0.8 mg/kg) or INDO (2 mg/kg) compared with control animals as shown. Note the similar changes induced by the 2 different treatments. (B) Hierarchical
cluster analysis performed on trigeminal ganglion genes showing a fold change of at least 1.4 (left) or 3 (right) between treated (ELE or INDO) and control animals.
Red, upregulated genes; green, downregulated genes. Note the correspondence between genes upregulated or downregulated in ELE- and INDO-exposed rats.
Venn diagram showing the number of genes upregulated or downregulated, as well as the degree of their overlapping, in the trigeminal ganglion of rats exposed to
ELE or INDO adopting a threshold of 1.4 (C) or 3 (D). ELE, eletriptan; INDO, indomethacin.
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Weperformeda hierarchical cluster analysis and found that genes
upregulated and downregulated by ELE were similarly affected by
INDO. Of note, profiles of differently expressed genes in trigeminal
ganglia were almost the same with the threshold of 1.4 and 3 (Fig.
1B). To corroborate this finding, we analyzed the array data by
means of the Venn diagram that describes the degree of overlapping
of transcriptomic changes between 2different treatments.We found
that with a threshold of 1.4, a large number of genes upregulated or
downregulated by ELE were similarly affected by INDO (Fig. 1C). A
high degree of overlapping was also found when the threshold was
set at 3 (Fig. 1D). The low number of inversely modulated genes
foundwith the threshold of 1.4was annulledwhen the thresholdwas
set at 3 (Figs. 1C and D), further suggesting a very high degree of
coherence of gene reprogramming within the trigeminal ganglion.
Table 1
Gene pathways downregulated or upregulated in the trigeminal ganglion of rats chronically exposed to ELE.
Gene-set name No. of altered genes Total no. of genes P Gene symbols
Pathways downregulated
Cell cycle: WP429 18 74 0.001 Bub1|Bub1b|Ccna2|Ccnb1|Ccne2|Cdc6|Cdk1|
Cdk4|Cdk6|Cdkn2a|Espl1|Hdac7|Mad2l1|Mcm2|
Mcm4|Mcm5|Mcm6|Pkmyt1
G1 to S cell cycle control: WP348 14 58 0 Ccnb1|Ccne2|Cdk1|Cdk4|Cdk6|Cdkn2a|Creb3l1|
Mcm2|Mcm4|Mcm5|Mcm6|Myc|Myt1|Pole2
Hedgehog signaling pathway: WP574 5 17 0.014 Ccnb1|Cdk1|Gli2|Ihh|Stk36
Nuclear receptors: WP217 7 36 0.014 Ar|Esr1|Nr0b1|Nr5a1|Pgr|Rorc|Thrb
DNA replication: WP484 7 37 0.019 Cdc6|Mcm10|Mcm2|Mcm4|Mcm5|Mcm6|Pole2
Pathways upregulated
Prostaglandin synthesis and regulation:
WP303
7 24 0.002 Anxa8|Edn1|Ednrb|Pla2g4a|Ptger3|Ptgis|Ptgs1
Spinal cord injury: WP2433 19 92 0.025 Aqp4|Ccl2|Cxcl1|Epha4|Gap43|Gfap|Gja1|
LOC102550316|Ltb|Mag|Ngfr|Pla2g2a|Pla2g5|
Prkca|Rhoc|Selp|Sema6a|Vim|Xylt1
GPCRs, class C metabotropic glutamate,
pheromone: WP42
5 15 0.008 Gprc5a|Gprc5b|Gprc5c|Grm4|Grm8
Keap1-Nrf2: WP1280 4 11 0.0075 Gsta2|Gsta5|Maf|Nqo1|Prkca
Eicosanoid synthesis: WP293 5 16 0.006 Alox5|Pla2g2a|Ptges|Ptgis|Ptgs1
Wnt signaling pathway and pluripotency:
WP1288
16 80 0.0375 Fzd1|Lef1|Nkd1|Nkd2|Plau|Ppm1j|Ppp2r2b|Prkca|
Prkcd|Prkcq|Tcf7|Wnt10b|Wnt11|Wnt16|Wnt2b|
Wnt6
Peptide GPCRs: WP131 11 50 0.048 Ccr1|Oprm1|Ednrb|Galr1|Npy1r|Npy5r|Oprk1|
Oprl1|Tacr3|Sstr4|Oprl
ELE, eletriptan.
Table 2
Gene pathways downregulated or upregulated in the trigeminal ganglion of rats chronically exposed to INDO.
Gene-set name No. of altered genes Total no. of genes P Gene symbols
Pathways downregulated
Cell cycle: WP429 14 74 0.001 Bub1|Bub1b|Ccna2|Ccnb1|Cdc6|Cdk1|Cdk6|
Cdkn2a|Espl1|Mcm4|Mcm5|Mcm6|Pkmyt1|Skp2
G1 to S cell cycle control: WP348 10 58 0.003 Ccnb1|Cdk1|Cdk6|Cdkn2a|Creb3l1|Mcm4|Mcm5|
Mcm6|Myc|Myt1
Hedgehog signaling pathway: WP574 4 17 0.022 Ccnb1|Cdk1|Gli2|Ihh
GPCRs, class B secretin-like: WP378 4 18 0.039 Cd97|Crhr1|Gcgr|Ghrhr
Nuclear receptors: WP217 6 36 0.0235 Ar|Esr1|Nr0b1|Nr4a2|Pgr|Rorc
GPCRs, other: WP409 8 59 0.0385 Cckbr|Celsr3|Drd4|Ghrhr|Gnrhr|Gpr143|Grm1|
Rxfp1
Pathways upregulated
Eicosanoid synthesis: WP293 6 16 0 Alox15|Alox5|Pla2g2a|Ptges|Ptgis|Ptgs1
GPCRs, class C metabotropic glutamate,
pheromone: WP42
5 15 0.0035 Gprc5a|Gprc5b|Gprc5c|Grm3|Grm8
Prostaglandin synthesis and regulation:
WP303
6 24 0.002 Anxa3|Anxa8|Ednrb|Pla2g4a|Ptgis|Ptgs1
Matrix metalloproteinases: WP278 6 24 0.0025 Mmp13|Mmp14|Mmp15|Mmp19|Mmp2|Mmp23
Peptide GPCRs: WP131 10 50 0.001 Ccr1|Ccr6|Ednrb|Galr1|Npy1r|Npy5r|Oprk1|Oprl1|
Sstr4|Tac4
Spinal cord injury: WP2433 16 93 0.038 Aqp4|Ccl2|Fcgr2a|Gfap|Gja1|LOC102550316|Ltb|
Mag|Ngfr|Pla2g2a|Pla2g5|Prkca|Rhoc|Sema6a|
Tnfsf13|Vim
INDO, indomethacin.
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We then performed a pathway analysis of differently expressed
genes adopting a threshold of 3. We found consistency among
some of the most significantly altered pathways. Specifically,
pathways downregulated by ELE and INDO were those involved
in cell-cycle regulation and nuclear receptors, as well as
Hedgehog signaling. Among the processes upregulated by both
treatments, we found prostaglandin synthesis, genes associated
with spinal cord injury, and signaling related to peptides acting on
G-protein-coupled receptors (Tables 1 and 2).
The high correspondence of upregulated and downregulated
genes by the 2 acute headache medications, prompted us to
focus on the expression levels of specific genes reported to be
of pathogenetic relevance to migraine and headache in general.
Fold change of transcript levels of the single gene is reported in
Figure 2. We found that genes coding for neuropeptides were
all increased to a similar extend by ELE and INDO. Specifically,
ELE and INDO increased CGRPa (Calca) transcripts by 4.52-
and 3.90-fold, respectively. Higher increases were found for
CGRPb (Calcb) transcripts that were augmented by 7.66- and
5.8-fold with ELE and INDO, respectively. PACAP (Adcyap1)
transcripts augmented in the trigeminal ganglion of ELE- or
INDO-treated rats by 4.11- and 2.87-fold, respectively. VIP (Vip)
dramatically increased in ELE- and INDO-exposed animals by
17.15- and 30.88-fold, respectively. Similarly, substance P
(Tac1) transcript levels were 3.68- and 3.43-fold higher than
control in ELE- and INDO-treated rats, respectively. NPY (Npy)
mRNA levels were augmented by ELE and INDO, showing
a 5.91- and 5.67-fold increase, respectively. As for somatostatin
(Sst) transcripts, again we found that they were increased by
ELE (1.70-fold) and INDO (1.68-fold). Similarly, transcripts for
the hypocretin neuropeptide precursor (Hcrt, leading to the
synthesis of orexins A and B) appeared decreased by both ELE
(22.2-fold) and INDO (21.82-fold). Calcitonin receptor–like
(Calcrl) transcripts were not changed by ELE, whereas
appeared increased by INDO by 1.82-fold. Conversely, RAMP1
transcripts were increased by both ELE and INDO by 3.45- and
3.64-fold, respectively. Expression levels of 5HT1BR (Htr1b)
appeared slightly decreased. Conversely, 5TH1DR (Htr1d)
levels showed increases of 6.07- and 4.72-fold with ELE and
INDO, respectively. Intriguingly, transcription of the key head-
ache pain transducers [TRPV1 and TRPA1 receptors4] was
increased. COX1 and COX2 appeared differently affected by the
treatments. COX1 transcripts were increased by both ELE
(3.89-fold) and INDO (3.28-fold), whereas those of COX2 did not
show substantial changes. Of note, mRNAs for prostaglandin
synthases that lay immediately downstream from COX and are
responsible for the synthesis of effector vasodilating prosta-
noids were also increased by the 2 drugs. In particular, PGE2
synthase (Ptges) increased by 3.79- (ELE) and 3.97-fold (INDO),
whereas a more pronounced increase of PGI2 synthase (Ptgis)
was found with ELE (18.5-fold) and INDO (19.56-fold). Finally,
eNOS (Nos3) transcript levels increased both with ELE (3.31-
fold) and INDO (1.83-fold) treatments; those coding for nNOS
(Nos1) appeared slightly increased only by INDO (1.59-fold),
whereas those coding for iNOS (Nos2) did not reach the
threshold of 1.4 with both drugs (Fig. 2).
Figure 2. Transcriptomic analysis of specific headache-related genes in the trigeminal ganglion of rats exposed to chronic treatment with eletriptan (ELE) or
indomethacin (INDO). The diagram shows the fold change of specific genes involved in headache pathogenesis selected from data obtained by the gene array
analysis shown in Figure 1. The thresholds of 1.4 and 3 are shown as horizontal dashed lines. Calca, CGRPa; Calcb, CGRPb; Adcyap1, PACAP; Vip, VIP; Tac1,
substance P; Npy, NPY; Sst, somatostatin; Hcrt, hypocretin; Calcrl, calcitonin receptor–like; Ramp1, RAMP1; Vipr1, VIP receptor 1; Vipr2, VIP receptor 2; Htr1b,
5HT1B receptor; Htr1d, 5HT1D receptor; Trpv1, TRPV1 receptor; Trpa1, TRPA1 receptor; Ptgs1, COX1; Ptgs2, COX2; Ptges, PGE synthase; Ptgis, PGI synthase;
Nos1, nNOS; Nos2, iNOS; Nos3, eNOS.
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3.2. Real-time polymerase chain reaction confirmation of hit
gene transcripts identified by gene array analysis
To corroborate our findings, we attempted to confirm the gene
array data by means of qPCR analysis of genes that showed
substantial expression changes. We therefore selected neuro-
peptides (CGRPa, PACAP, VIP, and somatostatin), TRP chan-
nels (TRPV1), cyclooxygenases (COX1 and COX2) as well as
serotonin receptors (5HT1BR and 5HT1DR). We extended this
qPCR analysis to the cervico-thoracic DRG to understand
whether gene expression changes induced by ELE and INDO
were restricted to the trigeminal ganglion.
As shown in Figure 3A, qPCR fully confirmed increased
expression of those genes identified by gene array analysis. In
keeping with gene array data, gene expression of 5TH1BR and
COX2 was not increased when evaluated by means of qPCR.
Remarkably, when transcript levels of genes found increased in
trigeminal ganglion were evaluated in thoracic DRG, only PACAP
and TRPV1 showed a tendency toward increase albeit without
reaching statistical significance (Fig. 3B). To mimic the clinical
condition that occurs in patients withMOHonce they undergo the
prototypical 1-week detoxification protocol,3,11 we analyzed
gene expression profiles in the trigeminal ganglion of rats 10
days after abrupt interruption of the 1-month treatment.We found
that on interruption, a complete recovery of gene expression
homeostasis occurs (Fig. 3C).
3.3. Evaluation of pain thresholds in rats chronically exposed
to ELE or INDO
We next wondered whether the pronociceptive transcriptome
alterations within the trigeminal ganglion of rats chronically
exposed to ELE or INDO correlated with a functional state of
orofacial allodynia and/or hyperalgesia. Alteration in pain thresh-
olds was also analyzed in the forepaw in light of lack of
transcriptional changes in the cervico-thoracic DRG. Interest-
ingly, we found that orofacial allodynia evaluated by measuring
tactile thresholds occurred in INDO- but not in ELE-exposed rats
(Fig. 4A). Conversely, a pain test conducted with a low
concentration of formalin showed that rats chronically treated
with ELE but not INDO were hyperalgesic displaying vigorous
orofacial rubbing behavior both during the early and delayed
phase after formalin injection (Fig. 4B). To corroborate this
finding, we also conducted a facial grimace test25 and found that
only rats receiving ELE showed impressive and prolonged facial
Figure 3. Real-time PCR confirmation of gene array data. Transcript levels of headache-related genes selected from Figure 2 have been quantified by means of
qPCR in the trigeminal ganglion (A) or thoracic DRG (B) of rats exposed to ELE or INDO and compared with control animals. (C) qPCR in the trigeminal ganglion 10
days after abrupt interruption of the 1-month treatment with ELE or INDO. Each column represents the mean6 SEM of 10 rats. *P, 0.05 vs control, the Student t
test. CGRP, calcitonin gene-related peptide; DRG, dorsal root ganglion; ELE, eletriptan; INDO, indomethacin; PCR, polymerase chain reaction.
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grimace on periorbital formalin injection (Figs. 4C and D). To rule
out the hypothesis that lack of periorbital sensitization was due to
the analgesic properties of INDO, we analyzed orofacial pain
intensity in rats injected with formalin at the suprathreshold
concentration of 0.5%. However, as shown in Figure 4E, rats
chronically exposed to INDO did not display reduced orofacial
rubbing when challenged with this concentration of formalin.
Evidence of altered facial nociception, along with that of
increased CGRP expression within the trigeminal ganglia of rats
exposed to chronic ELE or INDO treatment, prompted us to
investigate whether release of CGRP was also altered in these
animals. We therefore measured the peptide in blood collected
from the retro-orbital venous plexus after a challenge with
a subcutaneous capsaicin injection in the supraorbital region. In
keeping with transcriptional data, plasma levels of CGRP were
significantly higher in ELE- and INDO-treated rats compared with
controls (Fig. 4F). Next, we analyzed nociception thresholds at
the forepaws and found that, in keeping with data obtained in the
orofacial region, tactile threshold was only reduced in rats
exposed to INDO (Fig. 4G). However, both INDO- and ELE-
treated rats showed cold allodynia when evaluated with the cold
plate test (Fig. 4H).
4. Discussion
Medication-overuse headache represents the most frequent
transformation of chronic headache, leading to a clinical condi-
tion that exposes patients to severe secondary drug effects and
strengthens headache chronicization.5,6,10 This study shows that
chronic exposure to 2 different acute headache remedies such as
a triptan or an NSAID dramatically alters gene expression
homeostasis within the trigeminal ganglion, as well as pain
thresholds in the periorbital and forepaw regions. Importantly,
quantitative and qualitative derangement of gene expression
profiles is highly similar for both drugs, despite their different
mechanisms of action. To the best of our knowledge, this is the
first evidence that on chronic exposure to 2 different symptomatic
headache remedies, the trigeminal ganglion activates the same
Figure 4. Sensory thresholds in rats chronically exposed to ELE or INDO. (A) Tactile withdrawal thresholds (the Von Frey test) and (B) rubbing behaviour (0.2%
periorbital formalin) in rats exposed for 1 month to daily oral administrations of vehicle, ELE or INDO. (C) Grimace score in rats injected with 0.2% periorbital
formalin. (D) Representative images of rats during the grimace score. Note the obvious grimace in the animal chronically exposed to ELE. (E) Rubbing behaviour
(0.5%periorbital formalin) in rats exposed for 1month to daily oral administrations of vehicle, ELE, or INDO. (F) CGRP plasma level in blood collected from the retro-
orbital venous plexus after a challenge with a subcutaneous capsaicin injection in the supraorbital region. Tactile (G) and cold (H) withdrawal thresholds of the
forepaw in rats exposed to vehicle, ELE, or INDO. Each column represents the mean 6 SEM of 10 rats. *P, 0.05, *P, 0.01 vs vehicle. ANOVA plus the Tukey
post hoc test. ANOVA, analysis of variance; CGRP, calcitonin gene-related peptide; ELE, eletriptan; INDO, indomethacin.
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transcriptional program to increase sensitivity to nociceptive
stimuli. Notably, our preclinical data are in keeping with the clinic
of patients with MOH that, although overusing different types of
acute medications, invariably present the same pattern of
symptoms.5,6,10 Our findings are also in keeping with previous
work showing that repetitive exposure of rats to sumatriptan
prompts a condition of latent sensitization to nociceptive stimuli
concomitant with increased CGRP expression within the tri-
geminal ganglia.18–20,24
Currently, the exact neuroanatomical pathways and molecular
mechanisms participating to trigeminal ganglion transcriptional
reprogramming on chronic ELE or INDO exposure are unknown.
A simple interpretation might be that each drug acts on its
respective pharmacodynamic target on trigeminal ganglion
neurons to prompt different pathways that then converge to
prompt the same epigenetic reprogramming. Possibly, persistent
INDO-dependent inhibition of prostanoid synthesis within the
dura and other cranial structures, as well as changes in
meningeal/cerebral vessel dynamics due to chronic ELE can be
also sensed by peripheral trigeminal afferents that then signal
gene expression changes back to the ganglion. Even chronic
targeting of COX and 5HT1DR within the trigeminal nucleus
caudalis can be sensed by central trigeminal afferents and might
concur to resetting of gene expression in the ganglion. In light of
the high degree of similarity of the pattern of gene reprogramming
induced by ELE and INDO, we reason that signals originating
from chronic targeting of 5HT1DR and COX are integrated by
higher brain structures such as periaqueductal gray, hypothala-
mus, thalamus, and cortex6 that then reset, as a sort of
homeostatic feedback, trigeminal ganglion transcriptome, and
functioning. Regardless of the brain structures involved, it is worth
noting that high degree of consistency of gene resetting triggered
by the 2 drugs in the trigeminal ganglion is the first experimental
hint that a common neuroanatomical/neurochemical pathway is
shared by symptomatic headache medicaments to induce MOH.
Furthermore, given that clinical features of MOH due to triptans or
NSAIDs are essentially the same, it is likely that at least some of
the genes found reset in rats are indeed relevant to MOH
pathogenesis in patients.
This study indicates that transcriptional reprogramming in
the trigeminal ganglion prompts pain sensitization and is a key
neurobiological substrate of MOH. Accordingly, we found that
chronic INDO or ELE exposure leads to a pronociceptive state
of periorbital allodynia and hyperalgesia, in good keeping with
previous work from the Porreca group.18,19,24 It is worth
noting, however, that despite similar transcriptome alterations,
pain thresholds were not consistently affected by INDO and
ELE. Indeed, only INDO prompted facial tactile allodynia,
whereas periorbital hyperalgesia was found only in rats
exposed to ELE. Although we do not know the reason(s) of
this apparent discrepancy, we argue that events of synaptic
plasticity underlying both allodynia and hyperalgesia do not
lead to a static condition, but change over time and with
different temporal kinetics during chronic exposure to INDO or
ELE. These considerations taken together allow to speculate
that MOH originates from a homeostatic response of the
nervous system to chronic exposure to drugs such as
analgesics or triptans that, eventually, alters functioning of
the trigeminovascular system. Conversely, it is more difficult to
hypothesize that resetting of gene expression profiles oc-
curred because rats showed a drug dependence/addiction
substrate.9 Medication-overuse headache might be a sort of
compensatory state of trigeminal nociception when the latter is
constantly repressed by symptomatic headache medications.
From a neurophysiological perspective, reprogramming of the
trigeminovascular system with induction of pronociceptive
genes might be a feedback mechanism in an attempt to
reestablish pain thresholds.
The high degree of genomic plasticity induced by ELE and
INDO within the trigeminal ganglion is at odds with lack of gene
reprogramming in thoracic DRG. Previous work, however,
demonstrates that rats chronically exposed to sumatriptan
show allodynia not only in the periorbital region but also in the
hind paw.19 Consistently, we now report that those rats
exposed to INDO or ELE and showing no apparent alterations
of gene expression profiles within the DRG innervating the
forepaw do develop cold hyperalgesia in the same region. A
possible explanation for this apparent inconsistency might be
that sensitization of paws is due to spinal and/or supraspinal
mechanisms and not to events occurring at the DRG.
Accordingly, reduced supraspinal antinociceptive control has
been shown in patients with MOH,29 representing the
functional correlate of the high degree of maladaptive neuronal
plasticity that takes place within high brain structures during
migraine chronification.7 These results suggest, in keeping
with a very recent report,26 that the trigeminal ganglion shows
a peculiar, stereotyped (ie, drug-type independent) homeo-
static response to chronic symptomatic headache medica-
tions that render the trigeminovascular system unique among
other nociceptive pathways. This interpretation is also in
keeping with a study (and routine clinical practice) showing
that among patients with regular use of analgesics including
NSAIDs for rheumatologic disorders, none developed a pattern
of spontaneous peripheral pain accompanied by compulsive
medication consumption, reminiscent of a sort of “medication
overuse rheumatic pain.” Still, 8% of these rheumatologic
patients on chronic analgesics developedMOH, but, strikingly,
they all suffered from primary headache.1 Similarly, patients on
chronic opioids for ulcerative colitis develop MOH only if they
are migraineurs.37 This clinical information, along with present
data on gene reprogramming in the trigeminal ganglion of rats,
suggests that patients with headache have a neurophysiolog-
ical trait that predisposes them to develop headache once their
trigeminovascular system is in a state of latent pronociceptive
sensitization. Indeed, given that the rats we used were not
“migraineurs” despite their widespread trigeminal ganglion
reprogramming of gene expression profiles, we hypothesize
that the neurogenomic changes leading to pronociceptive
sensitization might in large part occur in all the individuals
exposed to repetitive analgesic intake. However, when they
occur in a subject susceptible to headache, the specific
neurophysiological substrate suffices to turn the latent
pronociceptive condition into an overt MOH.
In conclusion, this study furthers our understanding of the
complex pathophysiology of the trigeminovascular system in
condition of chronic exposure to symptomatic headache
medications. Additional studies, however, are needed to un-
derstand whether pronociceptive gene resetting also occurs in
the trigeminal ganglion of patients with MOH, as well as to unravel
neuroanatomy and neurochemistry underlying these genetic
alterations and how they translate to headache.
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